c-MET, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in various solid tumors like lung, breast, and liver cancers. Recent single-cell analysis has revealed that c-MET significantly impacts the composition of immune cells within the tumor microenvironment. It promotes an immunosuppressive environment by transforming anti-cancer M1 macrophages into tumorigenic M2 macrophages and converting CD4+Th cells into Treg cells by upregulating PD-L1, TGF-\u03b2, and IL-10. Our current research explores the potential of targeting c-MET as an immunotherapeutic strategy.<\/p>\n

<\/div>

<\/p>

Traditionally, c-MET was known to have a single ligand, HGF. However, our recent research has discovered new ligands for c-MET in breast cancer. These newly identified ligands can potentially disrupt anticancer immunotherapy efforts by altering the immune cell composition within the tumor microenvironment, ultimately hindering the body\u2019s ability to combat cancer effectively. This discovery highlights the need for a deeper understanding of c-MET\u2019s role in breast cancer and its implications for immunotherapeutic approaches.<\/p><\/div>\n

In our future team, we plan to jump much deeper into c-MET mechanism and the functional roles of interactions of c-MET with its novel ligands. The results have yet to be published.<\/span><\/span>
<\/p>\n\n\n\n\n

c-MET discovery subgroup
<\/h3>\n
The c-MET Discovery Subgroup represents a specialized research community dedicated to unraveling the intricacies of c-MET, a protein that has emerged as a pivotal player in cancer biology. This subgroup is deeply invested in understanding how c-MET influences the resistance mechanisms that cancer cells employ against targeted therapies and immunotherapies. They recognize the significance of c-MET in shaping the immunosuppressive microenvironment within tumors, which enables cancer cells to evade the body\u2019s natural defense mechanisms.<\/p><\/div><\/div><\/div><\/div><\/div><\/div>\n
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
Studies reviewed by this subgroup highlight several critical aspects of c-MET\u2019s role in cancer progression. They emphasize that c-MET\u2019s overexpression and hyperactivity are closely linked to the expression of PD-L1, a protein cancer cells use to shield themselves from the immune system. Moreover, c-MET activation appears to foster the transition of immune cells from an antitumor (M1) phenotype to a pro-tumor (M2) phenotype. It promotes the expansion of immunosuppressive T cells in the tumor microenvironment.<\/p>\n\n
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
Perhaps most intriguingly, the subgroup delves into the potential therapeutic implications of their findings. They have examined a bispecific antibody called amivantamab, which targets both c-MET and EGFR. This antibody has shown promise in enhancing the immune system\u2019s ability to combat cancer by engaging immune cells through an Fc-dependent mechanism. This discovery has paved the way for new therapeutic approaches that combine c-MET inhibition with immunotherapy, potentially offering a dual-pronged attack on tumorigenesis and immunosuppression.<\/p>\n
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
<\/p>
Overall, the c-MET Discovery Subgroup\u2019s research endeavors are instrumental in shedding light on the multifaceted roles of c-MET in cancer, offering hope for more effective treatments and personalized therapies for cancer patients. Their dedication to unraveling the complexities of c-MET\u2019s function in the context of cancer is paramount in advancing our understanding of this critical protein and its therapeutic potential.<\/p>\n\n\n
Antibody subgroup<\/h3>
<\/h2>\n\n
This specialized subgroup is dedicated to pioneering the development of \nmonoclonal antibodies (mAbs) tailored for innovative targets in cancer \nresearch. We embark on a journey of discovery, identifying novel \nbiomarkers and signaling pathways specific to various cancer types. \nLeveraging cutting-edge technologies, we engineer mAbs with \nunprecedented precision and affinity to selectively target these unique \nmarkers. Through rigorous preclinical assessments and clinical trials, \nwe aim to revolutionize cancer therapy by introducing a new class of \nhighly targeted treatments. Our commitment lies in reshaping the \nlandscape of cancer research and therapeutics, offering hope for more \neffective, personalized, and less toxic interventions in the fight \nagainst this complex disease.<\/p>
<\/p>\n
FDA watch subgroup
<\/h2>\n\n
<\/p>
<\/p>
<\/p>
The FDA watch subgroup monitors and analyzes decisions made by the U.S. Food and Drug Administration (FDA) regarding the approvals and withdrawals of pharmaceutical drugs. Their responsibility is to closely observe FDA actions and assess the implications of these decisions, particularly in the context of cancer therapy and immunotherapeutic interventions.<\/p>\n
<\/p>
<\/p>
<\/p>
This subgroup focuses on monitoring FDA actions related to immunotherapeutic drugs such as atezolizumab and nivolumab. When the FDA withdraws approvals for these drugs, the subgroup investigates the structural and clinical factors that influenced these decisions. They consider the impact of these withdrawals on patients, healthcare providers, and the pharmaceutical industry, recognizing the potential consequences for individuals suffering from specific cancers like TNBC and HCC.<\/p>\n
<\/p>
<\/p>
<\/p>
Furthermore, the FDA watch subgroup is critical in emphasizing the importance of continuous drug safety and efficacy evaluation, especially concerning immunogenicity and pharmacokinetics. Their work underscores the need for ongoing research to understand how these factors affect clinical outcomes. Additionally, they stay informed about advancements in cancer therapy, including developments in protein engineering and targeted protein degradation strategies, which could hold promise for future treatments.<\/p>\n\n\n\n\n\n\n\n
Our cutting-edge subgroup<\/span><\/h2>
<\/h2>\n
\n
Welcome\n to our High-Tech Bioinformatics Subgroup! In 2024, our research \nendeavors are fueled by innovation and focused on cutting-edge \ntechnologies. We have identified three priority areas that drive our \nprojects and shape the future of bioinformatics.<\/p><\/div><\/div><\/div><\/span><\/div><\/div>
\n
1) AI-based Bioinformatics:<\/strong>\n Artificial Intelligence (AI) is revolutionizing the field of \nbioinformatics. We\u2019re at the forefront of harnessing AI\u2019s power to \nanalyze biological data. By employing machine learning algorithms, we \ncan uncover hidden patterns, make predictions, and gain profound \ninsights into complex biological processes.<\/p>
2) Single-Cell Analytic Study:<\/strong>\n Understanding biology at the single-cell level is crucial. Our research\n delves into single-cell analytics, a field that allows us to dissect \nand analyze individual cells with precision. This approach unveils \nintricate details of cellular behavior, aiding in disease understanding,\n drug development, and personalized medicine.<\/p><\/div><\/div><\/div><\/span><\/div><\/div>
\n
3) Transferrable AI Models:<\/strong>\n Collaboration and knowledge sharing are essential in today\u2019s scientific\n landscape. We\u2019re seeking individuals well-versed in building \ntransferrable AI models. These models can be applied across various \nbiological datasets and domains, enhancing the efficiency and \neffectiveness of research.<\/p>
Join us on \nthis exciting journey into the future of bioinformatics. Together, we\u2019ll\n push the boundaries of knowledge, advance scientific discovery, and \nmake a lasting impact on the world of biology.<\/p><\/div><\/div><\/div><\/span><\/div><\/div>
<\/p>\n\n\n\n\n\n\n\n\n\n<\/body>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"pagelayer_contact_templates":[],"_pagelayer_content":"","_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-324","page","type-page","status-publish","hentry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"watson","author_link":"https:\/\/drparhamacademy.com\/main\/author\/watson\/"},"uagb_comment_info":0,"uagb_excerpt":null,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/pages\/324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/comments?post=324"}],"version-history":[{"count":5,"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/pages\/324\/revisions"}],"predecessor-version":[{"id":1150,"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/pages\/324\/revisions\/1150"}],"wp:attachment":[{"href":"https:\/\/drparhamacademy.com\/main\/wp-json\/wp\/v2\/media?parent=324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Research Direction
<\/h1>\n\n\n\n\n\n

Our International Collaboration
<\/h2>\n\n
<\/p>
<\/p>
<\/p>
<\/p>

Antibody subgroup<\/h3>

Research Direction<\/h1>\n\n\n\n\n\n

Our International Collaboration<\/h2>\n\n<\/p><\/p><\/p><\/p>

Antibody subgroup<\/h3>

Research Direction
<\/h1>\n\n\n\n\n\n

Our International Collaboration
<\/h2>\n\n
<\/p>
<\/p>
<\/p>
<\/p>